Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday

Aptevo Therapeutics (NASDAQ:APVO) is projected to release its results after the market closes on Tuesday, May 12th. Analysts expect Aptevo Therapeutics to post earnings of ($5.60) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, March 26th. The biotechnology company reported $118.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.10) by $126.33. On average, analysts expect Aptevo Therapeutics to post $-21 EPS for the current fiscal year and $-19 EPS for the next fiscal year.

Aptevo Therapeutics Stock Up 2.3%

Shares of APVO opened at $4.97 on Friday. The stock’s fifty day simple moving average is $5.07 and its 200-day simple moving average is $12.38. The firm has a market capitalization of $5.86 million, a PE ratio of 0.00 and a beta of 1.64. Aptevo Therapeutics has a 12-month low of $3.80 and a 12-month high of $258.01.

Analysts Set New Price Targets

APVO has been the subject of a number of recent analyst reports. Weiss Ratings downgraded Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, April 24th. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold”.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.